{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:57:50Z","timestamp":1761541070318},"reference-count":36,"publisher":"Japan Endocrine Society","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2012]]},"DOI":"10.1507\/endocrj.ej11-0023","type":"journal-article","created":{"date-parts":[[2011,10,12]],"date-time":"2011-10-12T05:20:51Z","timestamp":1318396851000},"page":"21-29","source":"Crossref","is-referenced-by-count":15,"title":["Plasma plasminogen activator inhibitor-1 levels in the different phenotypes of the polycystic ovary syndrome"],"prefix":"10.1507","volume":"59","author":[{"given":"Ekaterini","family":"Koiou","sequence":"first","affiliation":[{"name":"Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Tziomalos","sequence":"additional","affiliation":[{"name":"First Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, AHEPA Hospital, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Konstantinos","family":"Dinas","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilias","family":"Katsikis","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni A.","family":"Kandaraki","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Tsourdi","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stylianos","family":"Mavridis","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dimitrios","family":"Panidis","sequence":"additional","affiliation":[{"name":"Division of Endocrinology and Human Reproduction, Second Department of Obstetrics and Gynecology, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61345-2"},{"key":"2","unstructured":"2. Zawadski JK, Dunaif A (1992) Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GE, Hershman SM (eds) Polycystic ovary syndrome. Current issues in Endocrinology and Metabolism. Blackwell, Boston: 377-384."},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Rotterdam ESHRE\/ASRM-Sponsored PCOS Consensus Workshop Group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). <i>Hum Reprod<\/i> 19:41-47.","DOI":"10.1093\/humrep\/deh098"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Diamanti-Kandarakis E, Panidis D (2007) Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. <i>Clin Endocrinol<\/i> <i>(Oxf)<\/i> 67:735-742.","DOI":"10.1111\/j.1365-2265.2007.02954.x"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Moran L, Teede H (2009) Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. <i>Hum Reprod Update <\/i>15:477-488.","DOI":"10.1093\/humupd\/dmp008"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Carmina E, Lobo RA (2004) Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. <i>Fertil Steril<\/i> 82:661-665.","DOI":"10.1016\/j.fertnstert.2004.01.041"},{"key":"7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00171.x"},{"key":"8","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.51.4.1131"},{"key":"9","doi-asserted-by":"publisher","DOI":"10.2337\/diabetes.55.02.06.db05-1041"},{"key":"10","unstructured":"10. Baillargeon JP, Carpentier A (2007) Role of insulin in the hyperandrogenemia of lean women with polycystic ovary syndrome and normal insulin sensitivity. <i>Fertil Steril <\/i>88:886-893."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Gonz&aacute;lez F, Rote NS, Minium J, Kirwan JP (2009) Evidence of proatherogenic inflammation in polycystic ovary syndrome. <i>Metabolism <\/i>58:954-962.","DOI":"10.1016\/j.metabol.2009.02.022"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Lindholm A, Bixo M, Eliasson M, Hudecova M, Arnadottir R, Holte J, Poromaa IS (2010) Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. <i>Gynecol<\/i> <i>Endocrinol <\/i>26:743-748.","DOI":"10.3109\/09513590.2010.487592"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Orio F Jr, Palomba S, Cascella T, Tauchmanov&agrave; L, Nardo LG, Di Biase S, Labella D, Russo T, Savastano S, Tolino A, Zullo F, Colao A, Lombardi G (2004) Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? <i>Reprod Biomed Online <\/i>9:505-510.","DOI":"10.1016\/S1472-6483(10)61634-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Glueck CJ, Phillips H, Cameron D, Sieve-Smith L, Wang P (2001) Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study. <i>Fertil Steril <\/i>75:46-52.","DOI":"10.1016\/S0015-0282(00)01666-6"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Tan BK, Adya R, Chen J, Farhatullah S, Heutling D, Mitchell D, Lehnert H, Randeva HS (2009) Metformin decreases angiogenesis via NF-kappaB and Erk1\/2\/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. <i>Cardiovasc Res <\/i>83:566-574.","DOI":"10.1093\/cvr\/cvp131"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Moran LJ, Hutchison SK, Meyer C, Zoungas S, Teede HJ (2009) A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. <i>Clin Sci (Lond) <\/i>116:761-770.","DOI":"10.1042\/CS20080218"},{"key":"17","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.90684.2008"},{"issue":"5","key":"18","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/000456328302000502","volume":"20","year":"1983","ISSN":"http:\/\/id.crossref.org\/issn\/0004-5632","issn-type":"print"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1007\/BF00276993"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1210\/jc.85.7.2402"},{"key":"21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2265.1996.00863.x"},{"key":"22","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.51.467"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Slopien R, Lewandowski K, Kolacz E, Zawilska K, Warenik-Szymankiewicz A (2006) Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity. <i>Gynecol Endocrinol <\/i>22:651-654.","DOI":"10.1080\/09513590601005805"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Lovik A, Birkeland K (1995) Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. <i>Metabolism <\/i>44:611-616.","DOI":"10.1016\/0026-0495(95)90118-3"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Palomba S, Orio F Jr, Falbo A, Russo T, Tolino A, Zullo F (2005) Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. <i>Fertil Steril <\/i>84:761-765.","DOI":"10.1016\/j.fertnstert.2005.04.021"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G (2004) Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. <i>J Clin<\/i> <i>Endocrinol Metab <\/i>89:1273-1276.","DOI":"10.1210\/jc.2003-031205"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. <i>Am J Physiol<\/i> 237:E214-E223.","DOI":"10.1152\/ajpendo.1979.237.3.E214"},{"key":"28","unstructured":"28. Manner&aring;s-Holm L, Baghaei F, Holm G, Janson PO, Ohlsson C, L&ouml;nn M, Stener-Victorin E (2011) Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome. <i>J Clin Endocrinol Metab <\/i>96:1068-1076."},{"key":"29","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2004.11.026"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Boudreaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF (2006) Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. <i>Curr Diab Rep <\/i>6:77-83.","DOI":"10.1007\/s11892-006-0056-1"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-2724"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ (2008) Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. <i>J Clin Endocrinol Metab <\/i>93:1276-1284.","DOI":"10.1210\/jc.2007-0425"},{"key":"33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ehj.2003.11.004"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Smith A, Patterson C, Yarnell J, Rumley A, Ben-Shlomo Y, Lowe G (2005) Which hemostatic markers add to the predictive value of conventional risk factors for coronary heart disease and ischemic stroke? The Caerphilly Study. <i>Circulation <\/i>112:3080-3087.","DOI":"10.1161\/CIRCULATIONAHA.105.557132"},{"key":"35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055373"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Atiomo WU, Bates SA, Condon JE, Shaw S, West JH, Prentice AG (1998) The plasminogen activator system in women with polycystic ovary syndrome. <i>Fertil Steril<\/i> 69:236-241.","DOI":"10.1016\/S0015-0282(97)00486-X"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/59\/1\/59_EJ11-0023\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,13]],"date-time":"2021-04-13T06:05:51Z","timestamp":1618293951000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jstage.jst.go.jp\/article\/endocrj\/59\/1\/59_EJ11-0023\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej11-0023","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012]]}}}